{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:20Z","timestamp":1787027060439,"version":"build-2736575974"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Our objective was to systematically assess the prevalence and clinical features of adverse events related to interactions between cannabinoids and psychotropic drugs through a retrospective chart review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>1586 adverse event reports were assessed. Cases included in the analysis showed a high probability of a causal relationships between cannabinoid-psychotropic drug interactions and adverse events. Data extracted included age, sex, psychotropic drug, cannabinoid products, other medications, and the clinical outcomes and mechanisms of these interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cannabinoids were involved in 8% of adverse events associated with the concomitant use of psychotropic drugs and other preparations. We identified 20 reports in which side effects presented a causal relationship with the use of psychotropic drugs and cannabinoids. Preparations containing 18% or more tetrahydrocannabinol (THC), presented significant side effects with the following antidepressants: mianserine (restless legs syndrome, urogenital pain, ventricular tachycardia), mirtazapine (pancreatitis, hyperhidrosis, arthralgia), quetiapine (myocarditis, renal failure, bradycardia, sialorrhea), haloperidol (ventricular arrhythmia, prolonged QTc), aripiprazole (prolonged QTc), ventricular tachycardia) and cariprazine (stomach pain, hepatotoxicity), sertraline (ataxia, hyperactivity, coma, hallucinations, anxiety, agitation, tachycardia, panic attacks, disorientation, headache, dizziness, blurry vision, severe emesis, xerostomia, dry eyes), trazodone (disorientation, memory impairment, sedation), fluvoxamine (tachycardia, tachypnoea, dysarthria, auditory hallucinations). Two out of 20 reports (10%) analyzed in our study was related with the simultaneous use of cannabidiol (CBD) oil and sertraline. Concomitant use of those substances was associated with the adverse events in form of diarrhea, emesis, fever and severe fatigue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinicians need to closely monitor adverse events resulting from the combined use of cannabinoids and psychotropic medications. The accumulation of side effects and pharmacokinetic interactions (including CYP and p-glycoprotein inhibition) between these drugs can lead to clinically significant adverse outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1500312","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T01:00:11Z","timestamp":1729558811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs"],"prefix":"10.3389","volume":"15","author":[{"given":"Adrian Andrzej","family":"Chrobak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Woro\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Siwek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3390\/JCM8111819","article-title":"Medical cannabis for older patients\u2014treatment protocol and initial results","volume":"8","author":"Abuhasira","year":"2019","journal-title":"J. Clin. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/GERONT\/GNU034","article-title":"Promoting safe and effective use of OTC medications: CHPA-GSA National Summit","volume":"54","author":"Albert","year":"2014","journal-title":"Gerontologist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1007\/S11606-020-06504-8","article-title":"Cannabidiol interactions with medications, illicit substances, and alcohol: a comprehensive review","volume":"36","author":"Balachandran","year":"2021","journal-title":"J. Gen. Intern Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1124\/dmd.120.000073","article-title":"Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450","volume":"48","author":"Bansal","year":"2020","journal-title":"Drug Metabolism Dispos."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1080\/17512433.2022.2148655","article-title":"Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy","volume":"15","author":"Bardhi","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1124\/DMD.120.000350","article-title":"Cytochrome P450-catalyzed metabolism of cannabidiol to the active metabolite 7-hydroxy-cannabidiol","volume":"49","author":"Beers","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"B7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/CLPT.1980.139","article-title":"Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction","volume":"28","author":"Benowitz","year":"1980","journal-title":"Clin. Pharmacol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/WPS.21253","article-title":"Effects of cannabidiol on symptoms in people at clinical high risk for psychosis","volume":"23","author":"Bhattacharyya","year":"2024","journal-title":"World Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1124\/DMD.121.000505","article-title":"Tetrahydrocannabinol and its major metabolites are not (or are poor) substrates or inhibitors of human P-glycoprotein [ATP-Binding cassette (ABC) B1] and breast cancer resistance protein (ABCG2)","volume":"49","author":"Chen","year":"2021","journal-title":"Drug Metabolism Dispos."},{"key":"B10","first-page":"e372","article-title":"Efficacy and adverse effects of medical marijuana for chronic noncancer pain: systematic review of randomized controlled trials","volume":"61","author":"Deshpande","year":"2015","journal-title":"Can. Fam. Physician"},{"key":"B11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1208\/S12248-021-00616-7","article-title":"Cannabinoid interactions with cytochrome P450 drug metabolism: a full-spectrum characterization","volume":"23","author":"Doohan","year":"2021","journal-title":"AAPS J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/02791072.2019.1610199","article-title":"Characteristics associated with attitudes toward marijuana legalization in Michigan","volume":"51","author":"Ellis","year":"2019","journal-title":"J. Psychoact. Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1017\/S0033291717000046","article-title":"Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis","volume":"47","author":"Foglia","year":"2017","journal-title":"Psychol. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/EPI.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/EPI.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/J.EBCR.2017.10.001","article-title":"An interaction between warfarin and cannabidiol, a case report","volume":"9","author":"Grayson","year":"2017","journal-title":"Epilepsy Behav. Case Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000507998","article-title":"Delta-9-Tetrahydrocannabinol and cannabidiol drug-drug interactions","volume":"3","author":"Kocis","year":"2020","journal-title":"Med. Cannabis Cannabinoids"},{"key":"B18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4103\/0973-1229.104497","article-title":"Polypharmacy in psychiatry: a review","volume":"11","author":"Kukreja","year":"2013","journal-title":"Mens. Sana Monogr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1111\/AJT.15398","article-title":"Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus","volume":"19","author":"Leino","year":"2019","journal-title":"Am. J. Transpl."},{"key":"B20","doi-asserted-by":"publisher","first-page":"614811","DOI":"10.3389\/FPHAR.2021.614811","article-title":"Cannabidiol and amisulpride improve cognition in acute schizophrenia in an explorative, double-blind, active-controlled, randomized clinical trial","volume":"12","author":"Leweke","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e20193256","DOI":"10.1542\/PEDS.2019-3256","article-title":"Clinically significant drug-drug interaction between methadone and cannabidiol","volume":"145","author":"Madden","year":"2020","journal-title":"Pediatrics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/S12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"7397","DOI":"10.3390\/IJERPH19127397","article-title":"Trazodone prolonged-release monotherapy in cannabis dependent patients during lockdown due to COVID-19 pandemic: a case series","volume":"19","author":"Mazza","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/APPI.AJP.2017.17030325","article-title":"Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12906-016-1022-3","article-title":"Herbal medicine use behaviour in Australian adults who experience anxiety: a descriptive study","volume":"16","author":"McIntyre","year":"2016","journal-title":"BMC Complement. Altern. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archgenpsychiatry.2009.175","article-title":"National trends in psychotropic medication polypharmacy in office-based psychiatry","volume":"67","author":"Mojtabai","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/CPDD.665","article-title":"A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.24926\/IIP.V13I3.4890","article-title":"Hyponatremic cognitive dysfunction resulting from drug-drug-gene interaction between sertraline and cannabidiol in an intermediate CYP2C19 metabolizer patient","volume":"13","author":"Nanan","year":"2022","journal-title":"Innov. Pharm."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metabolism Dispos."},{"key":"B30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.17226\/24625","article-title":"The health effects of cannabis and cannabinoids","volume":"15","year":"2017","journal-title":"Psychiatria"},{"key":"B31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1176\/AJP.153.3.311","article-title":"Newer antidepressants and the cytochrome P450 system","volume":"153","author":"Nemeroff","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"B32","first-page":"285","article-title":"Tetrahydrocannabinol (THC)","volume-title":"Marijuana in America: cultural, political, and medical controversies","author":"Ng","year":"2023"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4177263","DOI":"10.1155\/2021\/4177263","article-title":"Acute extrapyramidal side effects from smoked haloperidol","volume":"2021","author":"Pham","year":"2021","journal-title":"Case Rep. Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3390\/JCM13061540","article-title":"\u03949-Tetrahydrocannabinol (THC): a critical overview of recent clinical trials and suggested guidelines for future research","volume":"13","author":"Pressman","year":"2024","journal-title":"J. Clin. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1001\/jamainternmed.2015.8581","article-title":"Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011","volume":"176","author":"Qato","year":"2016","journal-title":"JAMA Intern Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/JCP.0000000000001089","article-title":"The potential for pharmacokinetic interactions between cannabis products and conventional medications","volume":"39","author":"Qian","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-57369-0_1","article-title":"Constituents of cannabis sativa","volume":"1264","author":"Rock","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3389\/FPHAR.2016.00422","article-title":"Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence","volume":"7","author":"Rohleder","year":"2016","journal-title":"Front. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9781615371624","article-title":"The American psychiatric association publishing textbook of psychopharmacology","author":"Schatzberg","year":"2017"},{"key":"B40","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/PHAR.1747","article-title":"Treatment of cannabis use disorder: current science and future outlook","volume":"36","author":"Sherman","year":"2016","journal-title":"Pharmacotherapy"},{"key":"B41","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s43440-020-00058-6","article-title":"Adverse effects of interactions between antipsychotics and medications used in the treatment of cardiovascular disorders","volume":"72","author":"Siwek","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1271776","DOI":"10.3389\/FPHAR.2023.1271776","article-title":"Harder, better, faster, stronger? Retrospective chart review of adverse events of interactions between adaptogens and antidepressant drugs","volume":"14","author":"Siwek","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1055481","DOI":"10.3389\/fpsyt.2022.1055481","article-title":"Contemplating cannabis? The complex relationship between cannabinoids and hepatic metabolism resulting in the potential for drug-drug interactions","volume":"13","author":"Smith","year":"2023","journal-title":"Front. Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.3390\/pharmaceutics14122598","article-title":"Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020\u20132022)","volume":"14","author":"Souza","year":"2022","journal-title":"Pharmaceutics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/jpm11070615","article-title":"The impact of marijuana on antidepressant treatment in adolescents: clinical and pharmacologic considerations","volume":"11","author":"Vaughn","year":"2021","journal-title":"J. Pers. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3902740","DOI":"10.1155\/2020\/3902740","article-title":"Potential pharmacokinetic drug-drug interactions between cannabinoids and drugs used for chronic pain","volume":"2020","author":"V\u00e1zquez","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1472-6882-6-40","article-title":"Herbal medicine: women\u2019s views, knowledge and interaction with doctors: a qualitative study","volume":"6","author":"Vickers","year":"2006","journal-title":"BMC Complement. Altern. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2147\/TCRM.S363404","article-title":"Risks of digestive system side-effects of selective serotonin reuptake inhibitors in patients with depression: a network meta-analysis","volume":"18","author":"Wang","year":"2022","journal-title":"Ther. Clin. Risk Manag."},{"key":"B49","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/JCPH.1387","article-title":"A review of human studies assessing cannabidiol\u2019s (CBD) therapeutic actions and potential","volume":"59","author":"White","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"965432","DOI":"10.3389\/fphar.2022.965432","article-title":"Unprescribed and unnoticed: retrospective chart review of adverse events of interactions between antidepressants and over-the-counter drugs","volume":"13","author":"Woro\u0144","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"983","DOI":"10.12740\/PP\/OnlineFirst\/80998","article-title":"Unwanted effects of psychotropic drug interactions with medicinal products and diet supplements containing plant extracts","volume":"52","author":"Woro\u0144","year":"2018","journal-title":"Psychiatr. Pol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"977","DOI":"10.12740\/PP\/OnlineFirst\/96286","article-title":"Adverse effects of interactions between antidepressants and medications used in treatment of cardiovascular disorders","volume":"53","author":"Woro\u0144","year":"2019","journal-title":"Psychiatr. Pol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2174\/1389200217666151210142051","article-title":"Cannabinoids and cytochrome P450 interactions","volume":"17","author":"Zendulka","year":"2016","journal-title":"Curr. Drug Metab."},{"key":"B54","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1124\/JPET.105.098541","article-title":"Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana","volume":"317","author":"Zhu","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1500312\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T01:00:13Z","timestamp":1729558813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1500312\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":54,"alternative-id":["10.3389\/fphar.2024.1500312"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1500312","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]},"article-number":"1500312"}}